Physician profile
Michael S Grimley
NPI 1780641555
$50,909.41
in general payments reported to CMS, 2019-2025
9 companies · $18K in 2025
The $18K reported for 2025 was more than what 90% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $18K · 2023: $55.87 · 2024: $13K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Travel and Lodging: $4,970 · Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,007.50 |
| Travel and Lodging | $4,969.83 |
| Food and Beverage | $544.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $18,860.06 | 2023-2025 | |
| Swedish Orphan Biovitrum Ab | $18,478.78 | 2020 | |
| Gamida Cell INC. | $7,312.50 | 2025 | Aphexda |
| Biolinerx USA, INC. | $4,500.00 | 2024 | Aphexda |
| Merck Sharp & Dohme LLC | $800.18 | 2019 | |
| Cardinal Health 110 LLC | $550.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $175.00 | 2025 | Ultomiris |
| Incyte Corporation | $123.97 | 2025 | Niktimvo |
| Jazz Pharmaceuticals INC. | $108.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Grimley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.